SKYE

Skye Bioscience earns a Neutral rating with a 42.1 composite score and low conviction at 2/5. Regulatory is the strongest pillar at 49.0, supported by an 80.0 enforcement subscore and a 50.0 jurisdiction score, although weak filing cadence limits the contribution. Fundamentals follows at 44.0, where stronger revenue-growth and operating-margin subscores are offset by a 15.4 market-cap tier and 15.0 cash-runway score. Market contributes 40.0 despite unavailable pricing, while editorial ranks weakest at 30.0 because CIN newsroom coverage contains no recent newsroom or brief activity.

Licensed fundamentals data show no year-over-year revenue growth and a zero operating margin, leaving neither top-line expansion nor operating profitability as a current rating driver. The reported net loss of roughly $51 million and negative EBITDA of roughly $58 million reinforce the stretched financial condition, while the 2.4 cash-burn ratio and low cash-runway subscore preserve material financing pressure. A market capitalization near $24 million also constrains the fundamentals assessment. Primary regulatory filings show no dated latest filing, no events during either the 90-day or 180-day measurement windows, and no enforcement hits. That combination explains the regulatory pillar’s split profile: favorable enforcement scoring supports the rating, but a 25.0 cadence subscore prevents a stronger result. Institutional pricing feeds provide no current quote, limiting market confirmation, while CIN newsroom coverage supplies no incremental editorial validation.

The clearest forward catalyst sits within regulatory, the highest-scoring pillar. A current primary regulatory filing that establishes a consistent reporting cadence would directly address the weakest regulatory subscore while preserving the benefit from the clean enforcement record and midrange jurisdiction posture. Such a filing could strengthen visibility into operating progress, capital requirements, and the path away from the stretched condition, but the existing negative EBITDA and net loss keep conviction contained until fresh disclosure arrives. The single most important signal to watch is the timing and completeness of the next primary regulatory filing.